|
02.08.2017 23:52:00
|
Nektar to Announce Financial Results for the Second Quarter of 2017 on Tuesday, August 8, 2017, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Aug. 2, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2017, on Tuesday, August 8, 2017, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).
The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investors section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Monday, September 11, 2017.
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 62434800 (Nektar Therapeutics is the host)
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Contact:
For Investors and Media:
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
View original content:http://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-second-quarter-of-2017-on-tuesday-august-8-2017-after-close-of-us-based-financial-markets-300498783.html
SOURCE Nektar Therapeutics
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nektar Therapeuticsmehr Nachrichten
|
29.11.24 |
NASDAQ Composite Index-Papier Nektar Therapeutics-Aktie: So viel Verlust hätte eine Investition in Nektar Therapeutics von vor 10 Jahren bedeutet (finanzen.at) | |
|
27.11.24 |
Börse New York in Rot: Das macht der NASDAQ Composite am Nachmittag (finanzen.at) | |
|
22.11.24 |
Angespannte Stimmung in New York: NASDAQ Composite präsentiert sich mittags schwächer (finanzen.at) | |
|
22.11.24 |
NASDAQ Composite Index-Wert Nektar Therapeutics-Aktie: So viel Verlust hätte ein Investment in Nektar Therapeutics von vor 5 Jahren eingebracht (finanzen.at) | |
|
22.11.24 |
NASDAQ Composite aktuell: NASDAQ Composite zum Start in der Gewinnzone (finanzen.at) | |
|
15.11.24 |
Angespannte Stimmung in New York: NASDAQ Composite fällt schlussendlich (finanzen.at) | |
|
15.11.24 |
Börse New York in Rot: NASDAQ Composite präsentiert sich schwächer (finanzen.at) | |
|
15.11.24 |
Freitagshandel in New York: NASDAQ Composite sackt am Freitagmittag ab (finanzen.at) |
Analysen zu Nektar Therapeuticsmehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.